A multicenter phase II randomized trial of durvalumab (MEDI-4736) versus physician’s choice chemotherapy in recurrent ovarian clear cell adenocarcinoma (MOCCA)

BACKGROUND: The optimal treatment of recurrent ovarian clear cell carcinoma remains unknown. There is increasing rationale to support the role of immune checkpoint inhibitors targeting the programmed cell death protein 1 (PD-1)/programmed death-ligand 1 (PD-L1) axis in ovarian clear cell carcinoma....

Descripción completa

Detalles Bibliográficos
Autores principales: Ngoi, Natalie YL, Heong, Valerie, Ow, Samuel, Chay, Wen Yee, Kim, Hee Seung, Choi, Chel Hun, Goss, Geraldine, Goh, Jeffrey C, Tai, Bee Choo, Lim, Diana GZ, Kaliaperumal, Nivashini, Au, Veonice B, Connolly, John E, Kim, Jae-Weon, Friedlander, Michael, Kim, Kidong, Tan, David SP
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BMJ Publishing Group 2020
Materias:
Clinical Trial
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7418587/
https://www.ncbi.nlm.nih.gov/pubmed/32591370
http://dx.doi.org/10.1136/ijgc-2020-001604

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7418587/
https://www.ncbi.nlm.nih.gov/pubmed/32591370
http://dx.doi.org/10.1136/ijgc-2020-001604

Ejemplares similares